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Podoplanin is a transmembrane glycoprotein up-regulated in different human tumors, especially those derived from
squamous stratiﬁed epithelia (SCCs). Its expression in tumor cells is linked to increased cell migration and invasiveness;
however, the mechanisms underlying this process remain poorly understood. Here we report that CD44, the major
hyaluronan (HA) receptor, is a novel partner for podoplanin. Expression of the CD44 standard isoform (CD44s) is
coordinately up-regulated together with that of podoplanin during progression to highly aggressive SCCs in a mouse skin
model of carcinogenesis, and during epithelial-mesenchymal transition (EMT). In carcinoma cells, CD44 and podoplanin
colocalize at cell surface protrusions. Moreover, CD44 recruitment promoted by HA-coated beads or cross-linking with
a speciﬁc CD44 antibody induced corecruitment of podoplanin. Podoplanin–CD44s interaction was demonstrated
both by coimmunoprecipitation experiments and, in vivo, by ﬂuorescence resonance energy transfer/ﬂuorescence
lifetime imaging microscopy (FRET/FLIM), the later conﬁrming its association on the plasma membrane of cells with
a migratory phenotype. Importantly, we also show that podoplanin promotes directional persistence of motility in
epithelial cells, a feature that requires CD44, and that both molecules cooperate to promote directional migration in
SCC cells. Our results support a role for CD44-podoplanin interaction in driving tumor cell migration during
malignancy.
INTRODUCTION
Podoplanin (PA2.26 antigen, Aggrus, or T1) is a type I
transmembrane sialomucin up-regulated in different types
of cancer, such as squamous cell carcinomas (SCCs) and
testicular germ cell tumors (see Wicki and Christofori, 2007
for a review). Several reports support the involvement of
podoplanin in malignant progression. First, it has been
shown that podoplanin/Aggrus induces platelet aggrega-
tion facilitating tumor-platelet aggregate formation and me-
tastasis (Kunita et al., 2007). Second, we found that podopla-
nin/PA2.26 antigen promotes either cell scattering or a full
epithelial–mesenchymal transition (EMT) associated with
cell migration, invasion, and metastasis (Scholl et al., 1999;
Scholl et al., 2000; Martin-Villar et al., 2005; Martin-Villar et
al., 2006). Third, Wicki and colleagues reported that podo-
planin can promote collective tumor cell migration and in-
vasion in a pancreatic cancer mouse model (Wicki et al.,
2006). Because podoplanin lacks any obvious enzymatic mo-
tif within its structure, all these activities have to be medi-
ated by protein–protein interactions, hence the need to iden-
tify its binding partners. Thus, the binding of podoplanin
ectodomain to C-type lectin-like receptor 2 (CLEC-2) is in-
volved in podoplanin-induced platelet aggregation (Kato et
al., 2008), a process which is attenuated by the interaction of
podoplanin with CD9 tetraspanin (Nakazawa et al., 2008). In
addition, podoplanin-induced EMT is linked to RhoA acti-
vation and requires the association of the podoplanin cyto-
plasmic tail with ezrin and/or moesin, members of the ERM
(ezrin, radixin, moesin) protein family of membrane-cy-
toskeleton linkers (Martin-Villar et al., 2006).
In this report, we identify the standard isoform of CD44
(CD44s) as a novel partner for podoplanin. CD44 is a widely
distributed and highly polymorphic type I transmembrane
glycoprotein. Although it is encoded by a single gene, the
region comprising the extracellular domain includes 10 vari-
This article was published online ahead of print in MBoC in Press
(http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E10–06–0489)
on October 20, 2010.
‡ Present address for B.F.-M.: Centro de Biologia Molecular Severo
Ochoa, UAM, Cantoblanco, 28049 Madrid, Spain.
Address correspondence to: Ester Martín-Villar (ester.martin@kcl.
ac.uk) or Miguel Quintanilla (mquintanilla@iib.uam.es).
Abbreviations used: CD44s, CD44 standard isoform; CD44v, CD44
variant isoform; eGFP, enhanced green ﬂuorescent protein; EMT,
epithelial to mesenchymal transition; ERM, ezrin, radixin, moesin;
FRET-FLIM, ﬂuorescence resonance energy transfer–ﬂuorescence
lifetime imaging microscopy; HA, hyaluronan; SCC, squamous cell
carcinomas.
© 2010 E. Martín-Villar et al. This article is distributed by The
American Society for Cell Biology under license from the author(s).
Two months after publication it is available to the public under an
Attribution–Noncommercial–Share Alike 3.0 Unported Creative
Commons License (http://creativecommons.org/licenses/by-nc-
sa/3.0).
4387able exons (v1–10; CD44v) that can be alternatively spliced,
generating multiple isoforms (Screaton et al., 1992). CD44s
lacks all the variable exons and has a widespread tissue
distribution. An additional source of variation for all the
CD44 isoforms is glycosylation, which differ depending on
the type and activation state of the cell (Hathcock et al., 1993;
Skelton et al., 1998). CD44 functions as the major hyaluronan
(HA) receptor and mediates cell adhesion and migration in
a variety of pathophysiological processes, including tumor
metastasis, wound healing, and inﬂammation (Isacke and
Yarwood, 2002; Marhaba and Zoller, 2004). CD44 can also
act as a coreceptor modulating signal transduction through
cell-surface tyrosine kinase receptors. Interestingly, this
function depends on the ability of CD44 to bind ERM pro-
teins through its cytoplasmic tail (Ponta et al., 2003). The
podoplanin–CD44s interaction described here provides a
new mechanism by which both of these glycoproteins coop-
erate to promote cell migration and tumor progression.
MATERIALS AND METHODS
Cell Culture
Epidermal cell lines (Supplemental Table S1) were grown as described before
(Quintanilla et al., 2003). MDCK- and MCA3D-podoplanin cell transfectants
have been described previously (Scholl et al., 1999; Scholl et al., 2000; Martin-
Villar et al., 2006). HEK293T, HT1080, and MDCK-Snail1, -Snail2, and -E47
cells were a generous gift from Dr. Amparo Cano (Instituto de Investigaciones
Biomedicas Alberto Sols, Madrid, Spain). HN5 cells were kindly provided by
Dr. Marcella Flinterman (Oral Pathology Department, King’s College London,
London, UK). HaCaT, HEK293T, HT1080, HN5, and MDCK cells were grown
in Dulbecco’s Modiﬁed Eagle Medium (DMEM) supplemented with 10% fetal
calf serum, (Biosera, Sussex UK) 1% Pen-Strep (Sigma, Dorset, UK) and
L-glutamine (PAA Laboratories GmbH, Germany).
cDNA Constructs and RNA Interference
Full-length wild-type human podoplanin and mutant constructs subcloned
into the pcDNA3 and pEGFP vectors have been described elsewhere (Martin-
Villar et al., 2006). Human podoplanin and CD44s tagged with Hae and Flag
at the C terminus and mRFP-tagged CD44s constructs were obtained by PCR
ampliﬁcation using primers that carry convenient restriction sites to facilitate
subcloning into pcDNA3-Hae/Flag and pmRFP-N1 vectors. Oligonucleotides
used for ampliﬁcation of all these constructs are described in Table S2 in the
Supplemental material.
Short-hairpin RNAs (shRNAs) targeting human podoplanin mRNA were
cloned into pLKO.1 vector (Addgene, Cambridge, UK). Lentiviral superna-
tants were produced in HEK293T cells by cotransfection of pCMV-d8.9 (pack-
aging plasmid), pMD2G (envelope plasmid), and pLKO.1 including targeting
sequences and collected after 24 and 48 h. HN5 cells were grown at (70%)
conﬂuence and infected with lentiviral supernatants. After 48 h, infected HN5
cells were selected by addition of 1.4 g/ml puromycin (Sigma). Both podo-
planin target sequences, 5AAGACCGTTCACCAGACTTGG3 (podo sh1)
and 5AACACTGGACCATTGGATCGA3 (podo sh2), successfully knocked-
down expression of the target gene. For control experiments, cells were
infected with viral vectors containing scrambled shRNA (Addgene; ID 1864).
For CD44 down-regulation in MDCK cells following small interfering
(siRNA) oligonucleotides were used: 5 GACCACGACUCAUCGGUUC dT
dT3 and GAACCGAUGAGUCGUGGUC dT dT3. siRNA against Fireﬂy
luciferase GL3 was used as negative control (Elbashir et al., 2001).
For human CD44 knockdown the following siRNAs were used: 5GUAU-
GACACAAUAUUGCUUC dT dT3 and 5GAAGCAAUAUGUGUCAUAC
dT dT3 (Roscic-Mrkic et al., 2003). Control oligonucleotides where purchased
from Ambion (Warrington, UK; Silencer Negative control #1, AM4611). An-
nealed siRNA oligonucleotides were transfected with 100 M oligofectamine
(Invitrogen, Paisley, UK) in Opti-MEM reduced-serum medium (Invitrogen).
Cells were incubated at 37oC for 6 h before the addition of FBS to 10%. All the
assays were conducted at 48–72 h after transfection.
Mouse Skin Carcinogenesis
The two-stage mouse skin carcinogenesis (a single DMBA application fol-
lowed by twice weekly applications of TPA for 16 wk) was performed
following standard protocols (Perez-Gomez et al., 2007). Tumors were col-
lected at different time periods after initiation (papillomas at 30 wk and SCCs
at 43 wk) and processed for Western blotting. Tumors were histologically
typed by H&E staining of parafﬁn sections and characterized by the expres-
sion of the following differentiation/progression markers: keratins K1 and
K10, which are lost in SCCs; the extracellular matrix component SPARC,
which is induced during progression from papillomas to SCCs; as well as the
E-cadherin transcriptional repressor Snail1 and the enzyme lysyl oxidase-like
2, which accumulate in poorly differentiated SCCs, as previously described
(Perez-Gomez et al., 2007).
RT-PCR
Reverse transcription was performed as previously described (Martin-Villar
et al., 2006). For CD44 analyses speciﬁc primers were designed to amplify both
human and canine genes: 5-TATTGCTTCAATGCTTCAGCTCCA-3 and 5-
AGGTTGTGTTTGCTCCACCTTCTTGAC-3. PCR products were obtained
after 35 cycles of ampliﬁcation with an annealing temperature of 60°C.
Western Blot and Coimmunoprecipitation Experiments
For detection of podoplanin and CD44 in Western blots, cells or tissues were
lysed in buffer RIPA (0.1% SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40,
150 mM NaCl, 50 mM Tris-HCl pH 8.0) and a cocktail of protease inhibitors
(1 mM phenylmethylsulfonyl ﬂuoride, 2 g/ml aprotinin and 2 g/ml leu-
peptin). Samples containing the same amount of protein (10–30 g) were run
on 10% SDS-PAGE and transferred to Immobilon P membranes (Millipore,
Bedford, MA). Filters were then immunoblotted with the following Abs: anti
mouse podoplanin (PA2.26 mAb; previously described in Gandarillas et al.,
1997), anti human podoplanin (NZ1 mAb purchased from Acris Antibodies,
Herford, Germany), rat mAb IM7 against CD44 ectodomain (generously
provided by Dr Helen Yarwood; The Institute of Cancer Research, London,
UK), rabbit polyclonal Ab raised to the COOH terminal region of CD44
(CD44cyto, Abcam, Cambridge, UK), and mouse mAbs against -tubulin,
-actin (Sigma) and GAPDH (Roche Diagnostics, Welwyn Garden City, UK).
For coimmunoprecipitation experiments HEK293T cells were transiently
cotransfected with expression vectors using Effectene (Qiagen, Crawley, UK),
as indicated by the manufacturer. After 24 h, cells were lysed in IP buffer (50
mM Tris-HCl pH 8.0, 100 mM NaCl, EDTA 5 mM, 0.5% Triton X-100, 10%
glycerol) containing Complete Protease Inhibitors Cocktail Tablets (Roche
Diagnostics). Tagged CD44s-Hae or podoplanin-Flag proteins were immuno-
precipitated using anti-Hae (Roche Diagnostics) or anti-Flag (Sigma) mAbs
linked to protein A/G resin (Alpha Diagnostic, TX), respectively. After incu-
bation with 500–750 g of cell lysates for 2h at 4°C, the resin was then washed
ﬁve times with lysis buffer, and the coimmunoprecipitates were eluted in 1
Laemmli Buffer. Immunoprecipitation of endogenous podoplain in CarC cells
was performed using the PA2.26 mAb for mouse podoplanin and the coim-
munoprecipitated products were detected by using the rat mAb IM7 against
the CD44 ectodomain.
Coimmunoprecipitation assays of podoplanin-eGFP tagged constructs
were performed using an anti-GFP antibody-conjugated resin. The resin was
made by cross-linking a GFP polyclonal antibody (MBL International, Woburn,
MA) to the protein G beads using a Seize X protein G immunoprecipitation kit
purchased from Pierce Biotechnology (Leicestershire, UK). Coimmunoprecipita-
tion was done following the protocol provided by the manufacturer.
Bead and Antibody-Mediated Clustering Assays
Bead coating and incubation were performed as previously described (del
Pozo et al., 2004). Brieﬂy, 5-m polystyrene beads (Duke Scientiﬁc Corpora-
tion, Palo Alto, California) were washed in PBS and incubated with 5 mg/ml
BSA or 1 mg/ml high molecular mass HA (Sigma, H7630). Beads were left
overnight at 4°C to allow even protein binding, washed three times, and
resuspended in PBS to form a 50% slurry ﬁnal concentration. Coating efﬁ-
ciency of beads with HA was also tested by incubating the beads with
ﬂuorescently labeled HA (FITC-HA). Cells plated onto coverslips were incu-
bated with 5 l/ml coated-beads in growth media and incubated at 37°C for
15–30 min. Cells were then washed three times in medium and ﬁxed for
immunoﬂuorescence analysis.
Antibody-mediated clustering assays were performed as described previ-
ously (Clark et al., 2005). HN5 cells were platted on glass coverslips in DMEM.
To cluster CD44, CD44 mAb HP2/9 (generously provided by Dr. Francisco
Sa ´nchez-Madrid; Centro Nacional de Investigaciones Cardiovasculares, Ma-
drid, Spain) was incubated with cells in serum-free medium at a concentra-
tion of 1 g/ml for1ha t37°C. After three washes with warm PBS to remove
all nonbound Ab, a Cy3-labeled secondary Fc-speciﬁc Ab (2 g/ml), was
added for 1 h. Under these conditions the secondary Ab induces the cross-
linking of the primary Ab through its Fc-tail. This results in clustering the
protein of interest. After washing the samples three times with warm PBS,
cells were ﬁxed and processed for immunoﬂuorescence as described below.
FRET-FLIM Microscopy
FLIM was used to measure FRET between podoplanin eGFP constructs and
CD44s-mRFP in MDCK cotransfected cells. Podoplanin-eGFP and CD44-
mRFP constructs (at a Podoplanin-eGFP to CD44s-mRFP ratio of 1:3) or with
Podoplanin-eGFP alone were cotransfected using FuGene6 (Roche) according
to the manufacturer’s instructions. Cells were left to express the constructs for
48 h and then ﬁxed with 4% paraformaldehyde in PBS for 20 min, perme-
abilized with 0.01% Triton X-100/PBS for 10 min, and incubated with 1
mg/ml fresh Sodium Borohydride/PBS for 10 min at room temperature.
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time-correlated single-photon counting (for details see Parsons et al., 2008).
FLIM analysis to calculate eGFP lifetime and FRET efﬁciency was performed
using TRI2 software (developed by Paul Barber, Gray Cancer Institute, Lon-
don, UK).
Confocal Microscopy and Morphological Analysis
Cells on coverslips were ﬁxed with 3.7% formaldehyde for 30 min and
permeabilized with 0.05% Triton-X100/PBS for 10 min. Podoplanin and CD44
staining was carried out using the anti-human podoplanin mAb (NZ-1) and
the anti-CD44 HP2/9 mAb. Confocal images were acquired on a Leica TCS-
SP2 microscope for Figure 2A or on a NIKON A1 confocal laser-scanning
microscope for Figure 2, B and C and Figure 7. Images were assembled using
Leica confocal software 2.0 or NIS-Elements AR 3.0.
For morphological analyses cells were allowed to spread for 24 h and then
processed for immunoﬂuorescence. The actin cytoskeleton was visualized by
staining with Alexa Fluor 568-labeled phalloidin (Invitrogen). Tubulin was
detected using a speciﬁc mouse anti–-tubulin Ab (Sigma). Cell area was
quantiﬁed using the public domain program NIH ImageJ (developed at the
US National Institutes of Health).
Cell Migration Assays and Time-Lapse Microscopy
The migratory behavior of the cells was analyzed by using 8-m pore trans-
well chambers (Corning, Amsterdam, NE) and in vitro scratch assays. For
transwell assays MDCK cells were cotransfected with podoplanin-eGFP or
eGFP and CD44 or control siRNA. 2.5  104 cells per well were seeded 48 h
after transfection in DMEM containing 0.1% FBS and allowed to transmigrate
to 10% FBS medium for 12 h at 37°C. Cells on the upper side of the transwell
were then removed, and those on the underside were ﬁxed and stained with
crystal violet. Cell migration was quantiﬁed by counting the number of cells that
migrated through the inserts (three different ﬁelds per well were counted under
a NIKON Eclipse TS100 inverted light microscope, using a 10 objective).
Random migration analysis in MDCK cells was performed by time-lapse
ﬂuorescence microscopy. Cells were sparsely plated, grown in the absence of
serum, and imaged overnight. Pictures were taken every 5 min with the 10
objective of a Leica DMI6000B inverted ﬂuorescence microscope. Migration
was analyzed by Imaris 6.4.2 software to obtain cell trajectories and calculate
path length, displacement from origin, and average speed (total path length/
time). Persistence of migration (directionality) was deﬁned as displacement
from origin/total cell path.
For wound healing assays podoplanin- and/or CD44-depleted HN5 cells
were plated onto collagen I (BD Biosciences, Oxford, UK)-coated 12-well
plates and left for 24 h to form a monolayer. Conﬂuent monolayers were
scratched with a tip and cells were imaged in an atmosphere of 5% CO2 at
37°C with a 5 phase objective and an inverted microscope (Axiovert 100,
Carl Zeiss MicroImaging,) equipped with a charge-coupled device camera
(Sensicam;PCO) and motorized stage (Ludl). Images of the wounds were
collected every 10-min intervals for a period of 18 h. Image acquisition was
controlled by ANDOR IQ software. Sequences of images were quantitatively
analyzed using ImageJ software. Cell outlines were drawn along the wound
edge at time 0 h and 18 h. Migration was quantiﬁed by calculating the area
between the two outlines. Kinetics of migrating cells along the wound edge
were analyzed using the manual tracking tool in Image J and Mathematica 7.0
workbooks (Allen et al., 1998). Images and videos were assembled using
Image J and Adobe Premiere Pro1.5 software.
Statistics
All experiments were performed at least three times. Data are presented as
mean  SEM. Signiﬁcance was determined using one-way analysis of vari-
ance (ANOVA) followed by Bonferroni’s post test or two-tailed Student’s t
test. p  0.05 was considered statistically signiﬁcant. All statistical analyses
were performed using GraphPad Prism 4.0 software.
RESULTS
The Coordinate Expression of Podoplanin and CD44s
Correlates with Malignant Progression and EMT
We have previously shown that ectopic expression of podo-
planin in epithelial MDCK cells promoted a dramatic change
from an epithelial to a ﬁbroblastic-like morphology linked to
down-regulation of epithelial genes, such as E-cadherin, and
up-regulation of mesenchymal markers, such as ﬁbronectin
(Figure S1 in supplementary material; Martin-Villar et al.,
2006). When the levels of CD44 mRNA and protein were
analyzed in MDCK cells expressing podoplanin (MDCK-
Podo), a switch in the expression from CD44v isoforms to
CD44s was associated with the acquisition of a ﬁbroblastic
phenotype (Figure 1A). As shown in Figure 1B, this CD44
isoform switch was also seen in EMTs induced by the over-
expression of the E-cadherin repressors Snail 1, Snail 2, and
E47 in MDCK cells (Peinado et al., 2007).
EMT in mouse skin chemical carcinogenesis is associated
with progression from well-differentiated tumors to highly
aggressive undifferentiated or spindle cell carcinomas
(Akhurst and Balmain, 1999). Because podoplanin was iden-
tiﬁed as a cell-surface protein induced in keratinocytes dur-
ing mouse skin carcinogenesis (Gandarillas et al., 1997), we
analyzed CD44 and podoplanin expression in cell lines and
tumors corresponding to different stages of carcinogenesis
(Figure 1, C and D). In both cases, the coordinated up-
regulation of podoplanin and CD44s was associated with
the undifferentiated phenotype. CD44s was barely detected
in the normal epidermis and in benign papillomas, but it
was clearly induced in SCCs and further increased in poorly
differentiated tumors (Figure 1C). We, therefore, observed
an overall increase in CD44 expression that correlated with
malignant progression during carcinogenesis in vivo. Fur-
thermore, epithelial premalignant (MCA3D and PB) and
weakly metastatic carcinoma (PDV and B9) cell lines ex-
pressed low or null amounts of CD44s (Figure 1D); however,
its expression was signiﬁcantly enhanced in highly invasive
carcinoma cell lines exhibiting a ﬁbroblastic or spindle phe-
notype (HaCa4, A5, CarC, and CarB), and this increase
occurred concomitantly to down-regulation of CD44v. For a
summary of characteristics of the epidermal cell lines used
in this study, see Table S1 in supplemental material. Inter-
estingly, podoplanin expression followed a pattern roughly
similar to that of CD44s in tumors and cell lines (Figure 1, C
and D). The pair of cell lines B9 and A5 representing a
homogeneous model for malignant progression is illuminat-
ing in this respect. Both cell lines were derived from the
same carcinoma, B9 from the squamous component and A5
from the anaplastic spindle region (Burns et al., 1991). While
B9 neither expressed CD44s nor podoplanin, both glycopro-
teins were present in A5 cells (Figure 1D). Furthermore, the
ectopic expression of mouse podoplanin in pre-malignant
MCA3D keratinocytes promoted an EMT associated with
the acquisition of highly invasive and metastatic properties
(Scholl et al., 1999; Scholl et al., 2000) and the induction of
CD44s expression (Figure 1D). Both podoplanin and CD44s
protein levels were also increased in LN11 cells derived
from a lymph node metastasis produced by podoplanin-
expressing MCA3D cells (Figure 1D and Table S1).
Podoplanin Interacts with CD44s
The subcellular localization of CD44 in podoplanin-express-
ing cells was analyzed by confocal microscopy. Images re-
vealed that CD44 was distributed along the plasma mem-
brane, concentrated at cell surface protrusions where it
colocalized with podoplanin. This was the case for MDCK
cells expressing exogenous podoplanin tagged with eGFP
(PWT eGFP) and oral carcinoma HN5 cells expressing en-
dogenous podoplanin (Figure 2A). To determine whether
the binding of HA to CD44 affected the membrane localiza-
tion of podoplanin, PWT eGFP cells plated onto coverslips
were incubated with 5-m beads coated with HA. As shown
in Figure 2B, podoplanin was recruited by HA-coated beads
together with CD44. Binding was speciﬁc, as control BSA-
coated beads did not trigger recruitment of CD44 or podo-
planin. To analyze the possibility of a physical association
between podoplanin and CD44, we performed coclustering
experiments in PWT eGFP-expressing HN5 cells. These cells
were treated in vivo with an antibody raised to the CD44
ectodomain (HP2/9), and then the antibody was clustered
with a secondary antibody. This resulted in the formation of
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contacts (Figure 2C). Interestingly, CD44 clustering induced
corecruitment of PWTeGFP suggesting that both proteins are
associated either directly or indirectly within the plasma
membrane. Reciprocally, clustering of podoplanin also in-
duced corecruitment of CD44 (Figure S2).
We next studied the interaction of these proteins by co-
immunoprecipitation analysis. To this end, HEK293T cells
were cotransfected with constructs encoding podoplanin
and CD44s tagged with Flag and hemagglutinin (Hae)
epitopes at the COOH-terminal end, respectively (see in
Figure 5A a schematic representation of these constructs).
Expression of both molecules resulted to be heterogeneous
in their apparent molecular masses as several bands were
detected in the immunoblots (Figure 3 and Supplemental
Figure S3). We have previously shown that podoplanin het-
erogeneity in SDS-PAGE arises from the presence of O-
linked carbohydrates in its ectodomain (Scholl et al., 1999;
Martin-Villar et al., 2005). Similarly, molecular mass variabil-
ity of CD44s has been commonly attributed to glycosylation
changes, in particular N-linked oligosaccharides (Camp et
al., 1991; Skelton et al., 1998). Indeed, removal of N-linked
sugars in the CD44s protein conﬁrmed that extracellular
modiﬁcations were largely responsible for CD44s molecular
mass heterogeneity (Supplemental Figure S3, C and D). Im-
munoprecipitation experiments conﬁrmed that CD44 and
podoplanin coprecipitated with each other (Figure 3A). In-
terestingly, coprecipitated CD44s and podoplanin had a
lower molecular mass (45–65 kDa for CD44s, and 30 kDa
for podoplanin; Figure 3A and Supplemental Figure S3) than
that of the corresponding mature fully glycosylated forms,
indicating that the interaction between podoplanin and
CD44s could be dependent on the carbohydrate structure
present in the extracellular domain of both molecules. To
conﬁrm these results in a different cellular system, we also
performed immunoprecipitation assays using the SCC cell
line CarC, because it expresses high levels of podoplanin
and CD44s (Figure 1D). The occurrence of endogenous par-
tially glycosylated forms of both podoplanin (30 kDa) and
CD44s (70 kDa) was conﬁrmed in CarC lysates (Figure 3B).
Figure 1. Podoplanin and CD44 expression during EMT and mouse skin carcinogenesis. (A) Podoplanin-promoted EMT in MDCK cells is
associated with induction of CD44s expression. The phenotype of the cell lines is indicated: E, epithelial; F, ﬁbroblastic. The morphology and
characterization of these cells is shown in Supplemental Figure S1 and in Martin-Villar et al. (2006). The ﬁbrosarcoma HT1080 cell line was
used as a positive control for CD44s expression. Left and right panels show, respectively, the expression of CD44 transcripts (RT-PCR) and
proteins (Western blot). (B) CD44 protein expression in MDCK cells that underwent EMT by transfection of E-cadherin repressors Snail 1,
2, and E47. (C) CD44 and podoplanin protein expression in mouse normal epidermis and skin tumors induced by two-stage carcinogenesis.
All squamous cell carcinomas (SCCs) were excised at 43 wk post-initiation. SCCI-II, well to moderately differentiated; SCCIII-IV, poorly
differentiated. (D) CD44 and podoplanin protein expression in mouse epidermal cell lines (see table S1 for further information of the cells
lines). MCA3D keratinocytes forced to express podoplanin (MCA3D-Podo) undergo EMT. CD44s, CD44 standard isoform; CD44v, variant
CD44 isoforms. GAPDH and -tubulin/-actin were used as loading controls for RNA and protein, respectively.
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taed with a speciﬁc Ab recognizing murine podoplanin
(PA2.26 mAb). These results demonstrate that podoplanin
interacts with CD44s in SCC cells.
Podoplanin Binds CD44s at Cell-Surface Protrusions
The interaction of podoplanin with CD44s on the plasma
membrane of MDCK cells was also conﬁrmed in vivo by
ﬂuorescence resonance energy transfer (FRET) monitored by
the acceptor photobleaching method. The mean FRET efﬁ-
ciency value (n  8) between eYFP-tagged podoplanin (ac-
ceptor) and eCFP-tagged CD44s (donor) was 16% (Figure
S4). To further analyze the spatial relationship between po-
doplanin and CD44s in vivo we used ﬂuorescence lifetime
imaging microscopy (FLIM) to monitor FRET. This tech-
nique enables visualization and quantiﬁcation of protein–
protein interactions by analysis of the donor lifetime decay
kinetics (Parsons et al., 2008). Interaction of PWT eGFP (do-
nor) and CD44s-mRFP (acceptor) was observed in single
polarized cells, as measured by decreases in eGFP donor
ﬂuorescence lifetime relative to its lifetime in control cells
expressing PWT eGFP alone (Figure 4B, compare with panel
A). FRET was localized at the trailing edge during rear
retraction, and on small foci that were distributed through-
out the apical surface of the cell across the lamellae. Inter-
estingly, FRET efﬁciency was signiﬁcantly decreased in cells
in contact. Although speciﬁc interaction in the free lamellas
at the outer edge of the colonies was sometimes detected, no
interaction was observed at cell junctions, despite the pres-
ence of high levels of both molecules (Figure 4, B and C).
Moreover, stimulation of MDCK cell migration/scattering
with EGF or HGF increased the number of cells in which
podoplanin–CD44s complexes were present (data not shown).
Figure 2. Podoplanin and CD44 colocalize at cell-surface protru-
sions. (A) Confocal microscopy showing localization of endoge-
nous podoplanin and CD44 in HN5 oral carcinoma cells, and in
MDCK cells stably transfected with podoplanin-eGFP (PWT
eGFP). (B) Recruitment of both podoplanin and CD44 by HA-
coated beads (arrowheads). MDCK-PWT eGFP cells plated onto
coverslips were incubated with 5-m beads coated with BSA or
HA for 15 min. Cells were then processed for immunoﬂuores-
cence to detect CD44. (C) Ab-induced clustering of CD44 (HP2/9
mAb, red) induced corecruitment of PWT GFP (green) to CD44
patches (arrowheads) in HN5 cells. CD44 staining (blue) was
performed using a different CD44 mAb (IM7) to visualize total
distribution of CD44. Mouse IgGs were used as a negative con-
trol. Bars, 10 m.
Figure 3. Podoplanin coimmunoprecipitates with CD44s. (A)
HEK293T were transiently cotransfected with Flag-tagged human
podoplanin or Hae-tagged human CD44s, as indicated. After 24 h of
transfection, total lysates were immunoprecipitated with anti-Hae
or anti-Flag Abs. Immunoprecipitates were electrophoresed by 10%
SDS-PAGE and immunoblotted with anti-Flag or anti-Hae Abs,
respectively. Panels a and b represent different exposure times of
the same immunoblot. (B) Coimmunoprecipitation of endoge-
nous CD44 and podoplanin in the mouse carcinoma cell line
CarC. Lysates were immunoprecipitated with either a mAb spe-
ciﬁc for mouse podoplanin (PA2.26) or rat IgG as a control. The
presence of podoplanin and CD44s in the precipitate was deter-
mined with anti-podoplanin PA2.26 and anti-CD44 IM7 mAbs,
respectively. A longer exposure time of the input showing the
occurrence of a 70 kDa CD44s form in CarC lysates is shown in
the left panel. (C) Coimmunoprecipitation assay in HaCaT kera-
tinocytes. Note that HaCaT cells do not express podoplanin and
were used as negative control for the coimmunoprecipitation
assays depicted in panel B. Arrowheads indicate incompletely
glycosylated forms of CD44s (black arrowheads) and podoplanin
(open arrowheads).
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tion may contribute to a motile phenotype.
Podoplanin Binding to CD44s Is not Mediated by ERM
Proteins
The fact that podoplanin–CD44s interaction could be mon-
itored by FRET suggested that the molecules may interact
directly. However, because both CD44 and podoplanin bind
to ERM proteins through their cytoplasmic (CT) tails, we
also investigated the possibility that their interaction could
be mediated by ERM proteins. To analyze this, podoplanin
mutant constructs lacking the CT tail (PCT) or the ERM
binding site (PQNN) were used for FRET/FLIM experiments
(Figure 5A). As depicted in Figure 5B-C, preventing the
binding of ezrin/moesin to podoplanin (Martin-Villar et al.,
2006) did not impair CD44s–podoplanin interaction, indicat-
ing that it is not mediated by ERM proteins. To further
analyze which regions of the podoplanin molecule are im-
portant for podoplanin–CD44s binding we carried out co-
immunoprecipitation experiments in HEK293T cells. These
experiments were performed coexpressing CD44s-Hae and
several podoplanin mutant constructs fused to eGFP, in-
cluding PCT,P QNN and a mutant construct lacking the
extracellular domain (PEC). All these mutant proteins have
been previously characterized (Martin-Villar et al., 2006).
The ability of PEC mutant to interact with CD44s in vivo
could not be tested in FRET/FLIM experiments due to the
fact that the eGFP tag in this construct is located at the
NH2-terminal end of the fusion protein (Figure 5A). How-
ever, coimmunoprecipitation assays showed that only the
deletion of the podoplanin extracellular domain pre-
vented its interaction with CD44s (Figure 5D) conﬁrming
that ERM proteins are not required for podoplanin–CD44s
(ﬁgure 5D) association. Likewise, these results indicate
that the podoplanin ectodomain is a crucial region for its
binding to CD44.
Podoplanin-Induced Cell Migration and Directionality
Requires CD44
To analyze the contribution of CD44 to podoplanin-in-
duced cell migration, we performed transwell assays us-
ing MDCK cells transiently cotransfected with podopla-
nin cDNA and a small interfering (si)RNA to mediate
down-regulation of CD44. Conﬁrming our previous ﬁnd-
ings (Martin-Villar et al., 2006), PWT eGFP expression
increased MDCK cell migration 1.7-fold (Figure 6). The
knockdown of CD44 (70% reduction) did not signiﬁ-
cantly change the migratory behavior of MDCK-eGFP
cells. However, CD44 down-regulation prevented podo-
planin-enhanced migration, demonstrating that podopla-
nin requires CD44 to promote cell migration in MDCK
cells (Figure 6, A and B).
Our previous observations suggested that podoplanin
promotes intrinsic directional motility in MDCK cells (Mar-
tin-Villar et al., 2006). To further investigate this, MDCK cells
were imaged by ﬂuorescence time-lapse microscopy allow-
ing measurement of the total distance traveled, the displace-
ment from origin, and calculation of mean speed and direc-
tional persistence (Figure 6, C and D). The migration pattern
of control MDCK cells was erratic, with cells often changing
direction, while PWT eGFP-expressing cells frequently con-
tinued migrating in the same direction without turning.
Comparison of the migration tracks of a representative
number of cells for each condition showed that the direc-
tionality ratio was signiﬁcantly increased in podoplanin-
expressing cells, and that this was prevented when CD44
was knocked-down. Neither podoplanin expression nor
CD44 down-regulation affected the migration speed of
MDCK cells (Figure 6, C and D). Altogether, these results
demonstrate that CD44 plays a crucial role in podoplanin-
mediated migration.
Podoplanin and CD44 Depletion Alters Lamellipodia
Extension/Stabilization and Cell Spreading
To further analyze the role of the podoplanin–CD44 com-
plex in the migration of tumor cells, we down-regulated the
Figure 4. Podoplanin–CD44s complexes at the plasma membrane
are up-regulated in cells with a migratory phenotype. (A–C) Mul-
tiphoton FLIM was used to image FRET between PWT eGFP (donor)
and CD44s-mRFP (acceptor) in MDCK cells. The images show the
eGFP multiphoton intensity image and (where appropriate) the
corresponding wide-ﬁeld CCD camera image of mRFP expression.
Lifetime images mapping spatial FRET across the cells are depicted
using a pseudocolor scale (blue, normal eGFP lifetime; red, FRET).
(A) Control MDCK cells expressing PWT eGFP alone demonstrated
a normal GFP lifetime ( in ns) in the absence of acceptor. (B) Cells
coexpressing PWT eGFP and CD44s-mRFP display a localized short-
ening of the eGFP ﬂuorescence lifetime, which is demonstrated by
red in the pseudocolor scale. Note that although colocalization
between PWT eGFP and CD44s–mRFP was always detected, FRET
was recorded mainly in isolated cells (i.e., those that had detached
from their neighbors). (C) Bar graph representing average FRET
efﬁciency of 14 cells for each condition over three independent
experiments. The Student’s t test was used to evaluate statistical
signiﬁcance between different populations of data. ***p  0.0005.
E. Martín-Villar et al.
Molecular Biology of the Cell 4392expression of both molecules in the SCC cell line HN5,
which expresses high levels of endogenous podoplanin and
CD44. We used a vector-based small hairpin (sh)RNA ap-
proach to deplete podoplanin, in combination with an al-
Figure 5. Podoplanin–CD44s interaction is not mediated by ERM proteins. (A) Schematic representation of podoplanin and CD44s fusion
constructs used for coimmunoprecipitation and FRET/FLIM assays. SP, signal peptide; Ec, ectodomain; TM, transmembrane domain; CT,
cytoplasmic tail; QN N, positive charged residues (RK.R) in podoplanin juxtamembrane domain were substituted by uncharged polar amino
acids (QN.N) in order to impair podoplanin binding to ERM proteins (Martin-Villar et al., 2006). (B) MDCK cells were cotransfected with CD44s
mRFP and podoplanin eGFP mutant constructs, and cells were then imaged by FLIM to detect FRET as depicted in Figure 4. Images show the eGFP
multiphoton intensity image and (where appropriate) the corresponding wide-ﬁeld CCD camera image of the mRFP expression. Control MDCK
cells expressing PWT,P CT,o rP QNN eGFP alone showed a normal GFP lifetime ( in ns) in the absence of acceptor (CD44s mRFP), while cells
coexpressing CD44s mRFP and podoplanin mutant constructs displayed a localized shortening of the eGFP ﬂuorescence lifetime. (C) The bar graph
represents average FRET efﬁciency of 15 cells over three independent experiments. (D) Coimmunoprecipitation assays performed in HEK293T cells
coexpressing CD44s Hae and podoplanin eGFP mutant constructs. Total cell lysates were immunoprecipitated with an anti-GFP Ab-conjugated
resin as described in Materials and Methods. The coimmunoprecipitated products were detected with an anti-Hae Ab.
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human cells (Tzircotis et al., 2005). As depicted in Figure 7A,
CD44 expression was efﬁciently down-regulated (70%),
and similarly, podoplanin protein levels were almost
completely suppressed (90% reduction) by using two
different shRNAs (podo-sh1 and -sh2). A signiﬁcant
siRNA-mediated reduction of CD44 levels (80%) was
also achieved in podoplanin-depleted cells. siRNA medi-
ated down-regulation of CD44 seemed not to affect podo-
planin expression and vice versa.
Control cells usually displayed a characteristic highly or-
ganized leading edge with well-extended lamellipodia ex-
tensions, and the microtubule network often aligned parallel
to, but localized at a considerable distance from, the leading
edge. Interestingly, the single knockdown of CD44 enhanced
cell spreading whereas the opposite was found to occur by
silencing podoplanin expression alone (Figure 7, B and C).
CD44si cells extended wide lamella with clear marginal
F-actin rufﬂes. These cells also showed a well organized
microtubule network (Figure 7B). Podoplanin-deﬁcient cells,
Figure 6. Podoplanin-induced migration and directionality in MDCK cells requires CD44. (A) Expression levels of podoplanin (PWT eGFP)
and CD44 after PWT eGFP and CD44 siRNA coexpression. -actin was used as a loading control. Arrowheads indicate fully (black
arrowheads) and incompletely glycosylated (open arrowheads) forms of PWT eGFP. (B) Transwell migration assay. Bar graph representing
percentage of migrating cells per total number of cells. Results are representative of three independent experiments performed in duplicates.
(C) Representative migration tracks of MDCK cells expressing PWT eGFP in the presence or absence of CD44 (n  30). (D) Average persistence
and speed of migration derived from the tracks depicted in C. n  40–85 cells per bar. Asterisks indicate signiﬁcant differences in a Student’s
t test. **p  0.005, *p  0.05.
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These cells were unable to extend typical broad lamellipo-
dia, exhibiting narrower (ﬁlopodia-like) protrusions instead,
and the microtubules penetrated into the leading edge area
(Figure 7B). RNAi-mediated knockdown of endogenous
CD44 in podoplanin-deﬁcient cells did not signiﬁcantly
change the cell shape of these cells (Figure 7, B and C). These
results point to a role of the podoplanin–CD44 complex in
regulating lamellipodia extension/stabilization during cell
spreading and migration.
Podoplanin and CD44 Cooperate to Promote Directional
Cell Motility during Wound Healing
To assess whether the observed morphological changes in
single and double knockdown HN5 cells were coupled with
defects in cell motility, we performed an in vitro wound
healing assay. Time-lapse video microscopy was used to
monitor wound closure. All the control cell lines showed
95% wound closure 18 h after wounding. Podo-sh1 and
sh2 cells covered 40 and 60% of the control area, respec-
tively, and CD44si cells covered 20–30% in the same period
of time. Interestingly, wound closure delay became signiﬁ-
cantly more evident in double knockdown cells, as only
2–10% of the wound area was covered (Figure 8B and Movie
1 in supplemental material). Subsequently, we analyzed the
migration pattern of a representative number of cells at the
wound edges for a time period of 6 h. When the migration
tracks were graphed to show directionality, it was evident
that down-regulation of either podoplanin or CD44 alone
resulted in a more random, less directional movement of
cells positioned along the wound edge (Figure 8, A and C
and Movie 2 in supplemental material). Moreover, by silenc-
ing both molecules the migration of HN5 cells toward the
wound was almost suppressed. Altogether, these results
strongly indicate that podoplanin and CD44 collaborate to
promote directional motility.
DISCUSSION
Podoplanin and CD44 are type I membrane glycoproteins
that are anchored to the actin cytoskeleton through associa-
tion with ERM proteins (Legg and Isacke, 1998; Yonemura et
al., 1998; Scholl et al., 1999; Martin-Villar et al., 2006), and
both are involved in cell adhesion, motility, and signal trans-
duction despite lacking intrinsic kinase activity (reviewed in
Ponta et al., 2003; Wicki and Christofori, 2007). In this study,
we report CD44 as a novel binding partner for podoplanin
and describe a close relationship between CD44s and podo-
planin expression associated with EMT and advanced stages
of tumor progression in an experimental model of carcino-
genesis. Although studies regarding expression of CD44
isoforms in human cancer are contradictory (Marhaba and
Zoller, 2004), it has been proposed that a switch from CD44v
to CD44s expression is a feature of poorly differentiated
Figure 7. Knockdown of CD44 and podoplanin in oral carcinoma HN5 cells affects cell spreading. (A) Expression levels of CD44 and
podoplanin in single and double knockdown cells by Western blot analysis. The expression of GAPDH was used as a loading control. (B)
Immunoﬂuorescence detection of F-actin and microtubules in single and double knockdown cells. Cells were double stained for F-actin (red)
with phalloidin and microtubules (green) with a speciﬁc anti-tubulin mAb. Note the extremely disorganized leading edge of podoplanin-
deﬁcient cells and double knockdown cells (arrowheads) compared with control cells. (C) Graphical representation of the cell spread areas
quantiﬁed using Image J software as described in Materials and Methods (n  40–50 cells per bar). P values were obtained using a one-way
analysis of variance (ANOVA). *p  0.05; **p  0.005; ***p  0.0005. Bars, 10 m.
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conclusion from the analysis of both tumors and cell lines
derived from the mouse skin carcinogenesis model is that
despite the high heterogeneity of CD44 expression in vivo, a
clear CD44s (and podoplanin) up-regulation is observed
associated with the loss of differentiation in skin carcinomas.
Similarly, increased expression of podoplanin has been as-
sociated with poor clinical outcome and metastasis in hu-
man SCCs (Yuan et al., 2006; Chuang et al., 2009). Interest-
ingly, a recent study has found that podoplanin and CD44
were coexpressed in cells localized at the periphery of tumor
nests in a high proportion of SCCs of the lung, although the
distribution of CD44 was broader than that of podoplanin
(Shimada et al., 2009). Moreover, CD44 is a common cell-
Figure 8. Knockdown of CD44 and podoplanin in oral carcinoma
HN5 cells impairs directional migration during wound healing. (A)
Analysis of the migration pattern at the wound edge of podoplanin and
CD44 knocked-down HN5 cells. The migration paths of representative
cells taken from the wound edge are indicated on an overlay image
from the initiation of the imaging (0 h). Images of the wounds at 6 h
after the incision was made are shown in the middle panel. Trace of the
movement of multiple cells along the wound edge (n  30) are shown
in the graphs of the right panel. (B) Quantiﬁcation of the wound closure
after 18 h. (C) Average persistence of migration (directionality) from the
tracks depicted in A. An animate and complete (18h) sequence of these
data are shown in Supplemental Movies 1 and 2. P values were ob-
tained using one-way analysis of variance (ANOVA). *p  0.05; **p 
0.005, ***p  0.0005.
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vader and Lindeman, 2008), and podoplanin has recently
been postulated as a novel candidate marker of SCC stem
cells, where it was coexpressed with CD44 (Atsumi et al.,
2008). These data suggest that there is a subpopulation of
carcinoma cells with stem-like properties that coexpress
podoplanin and CD44. While the biological signiﬁcance of
the presence of both proteins in cancer stem cells is still
uncertain, it is tempting to speculate that coexpression of
podoplanin and CD44s identify a cancer stem cell sub-
population with a high potential to disseminate and me-
tastasize because of its association with EMT and the
undifferentiated state of SCCs (Polyak and Weinberg,
2009).
Interestingly, we also found that podoplanin and CD44s
interact to form a dynamic complex at the plasma membrane
of migratory cells. This interaction seems to be direct, as it is
not mediated by their common partners ezrin/moesin, and
might be dependent on extracellular modiﬁcations of both
glycoproteins. Supporting this hypothesis is the ﬁnding that
the extracellular domain of podoplanin appears to be crucial
for its association with CD44s. Accordingly, podoplanin in-
teractions with other proteins such as CLEC-2 (Kato et al.,
2008) or galectin-8 (Cueni and Detmar, 2009) have been
found to be dependent on the carbohydrate moieties present
in their ectodomains. Moreover, it has been recently re-
ported that recombinant soluble forms of the podoplanin
ectodomain with different degrees of glycosylation can de-
crease cell adhesion and migration of lymphatic endothelial
cells. Interestingly, in this study, the less glycosylated forms
were more effective than the more extensively glycosylated
proteins (Cueni et al., 2010). CD44 is known to undergo
sequential proteolytic cleavages that have an important role
in cell migration (reviewed in Nagano and Saya, 2004). For
this reason, one could argue that the CD44 forms (45–70
kDa) coprecipitating with podoplanin might be fragments of
the molecule rather than less glycosylated proteins. How-
ever, these forms were recognized either by antibodies
raised to the CD44 NH2-terminal end (IM7: Figure 3B) or to
its CT tail (anti-CD44cyto Ab or anti-Hae Ab; Figure 3A and
Supplemental Figure S3), indicating that these forms are not
processing products of 80-kDa CD44s. Moreover, inhibition
of CD44 proteolysis did not alter the pattern of CD44s co-
precipitating forms (Supplemental Figure S3). On the other
hand, removal of N-linked oligosaccharides in the CD44s
molecule gave rise to protein forms of 45–70 kDa with
similar apparent molecular masses as the ones precipitated
together with podoplanin. Glycosylation has been impli-
cated in the regulation of CD44-mediated cell binding to
HA, as well as in CD44 association with the actin cytoskel-
eton (Thorne et al., 2004). The fact that podoplanin–CD44s
interaction preferentially occurs when both molecules are
not heavily glycosylated allows us to speculate that this
association could be regulated by the glycosylation status of
both molecules. Further investigations to address the mech-
anisms that regulate podoplanin–CD44s complex formation
and its dependence on differential glycosylation are cur-
rently in progress.
Podoplanin–CD44s interaction appears to occur mainly on
the trailing edge and on discrete foci on the lamella. Because
both proteins can activate RhoA GTPase through binding to
ERM proteins (Hirao et al., 1996; Martin-Villar et al., 2006),
and RhoA-ROCK activity is required for actomyosin-based
cortical contractility leading to detachment of the trailing
edge (Ridley, 2001), podoplanin–CD44s interaction might be
associated with tail retraction during mesenchymal-type of
tumor cell movement (Friedl and Wolf, 2003). However, it is
not clear yet how binding of these molecules to ERM pro-
teins affects podoplanin–CD44s association and whether po-
doplanin–CD44s interaction inﬂuences signal transduction
pathways mediated by any of these two molecules. On the
other hand, knockdown of CD44 in HN5 oral SCC cells
resulted in increased spreading and formation of extended
lamella, while the opposite effect was observed upon silenc-
ing podoplanin expression. Moreover, knockdown of CD44
in podoplanin-deﬁcient cells did not change signiﬁcantly the
shrunken shape characteristic of these cells. These results
also suggest an involvement of podoplanin in lamellipodial
extension/stabilization and spreading that is regulated by
CD44. What strongly emerges from our gain- and loss-of-
function experiments is the notion that podoplanin and
CD44 cooperate to stimulate directional motility. Thus, po-
doplanin enhances the intrinsic directional motility of
MDCK cells migrating either randomly or in a chemotactic
transwell assay, and this effect is abolished by knocking-
down CD44. Likewise, single knockdown of either CD44 or
podoplanin inhibited the migratory potential of HN5 carci-
noma cells in an in vitro wound healing assay, and depletion
of both molecules almost suppressed the migration of HN5
cells toward the wound. Both CD44 and podoplanin appear
to be required for cells to maintain direction during move-
ment, as the knockdown of any of them resulted in less
directional migration. Previous studies have found an im-
portant role for CD44 in mediating directional migration of
different cell types, including cancer cells (Miletti-Gonzalez
et al., 2005; Tzircotis et al., 2005; Colone et al., 2008). Interest-
ingly, in neutrophils and ﬁbroblasts, CD44 is characteristi-
cally localized at the trailing edge of polarized cells (Jacob-
son et al., 1984; Seveau et al., 2001). It has been found that the
binding of CD44 to ezrin is crucial for CD44-dependent
directional motility (Legg et al., 2002). Also, podoplanin
mutant proteins unable to bind ezrin/moesin confer less
motile phenotypes than wild-type podoplanin when ex-
pressed in MDCK cells (Martin-Villar et al., 2006). However,
it remains to be investigated whether podoplanin associa-
tion with ERM proteins controls podoplanin-dependent di-
rectional motility as occurs with CD44.
Interest in podoplanin has considerably increased over the
years because of its up-regulation in different human tu-
mors, especially those derived from squamous stratiﬁed
epithelia. However, many aspects of the biology and func-
tion of this glycoprotein still remain elusive. The lack of any
obvious functional domains in the podoplanin molecule
highlights the need to identify its binding partners. Simi-
larly, the precise mechanisms controlling the structural and
signaling events associated to CD44 have yet to be eluci-
dated. In summary, the data presented here demonstrate
that podoplanin associates with CD44s and that this inter-
action is important for driving directional cell migration in
epithelial and tumor cells. Determining how this interaction
is regulated could help to clarify many open questions in the
biology of both molecules.
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